Thus, the reduction of D-2HG levels via small molecule inhibition of mutant IDH activity has been pursued as a therapeutic strategy in IDH-mutant glioma over the last decade, resulting in the FDA approval of the dual mutant-IDH1/2 inhibitor vorasidenib for the treatment of low-grade IDH-mutant glioma. This evidence concerns the gene IDH2 and glioma.